US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

7.74

+0.22002.93%

Volume:3K

Turnover:26.05K

Market Cap:31.31M

PE:0.17

High:7.74

Open:7.67

Low:7.67

Close:7.52

52wk High:12.60

52wk Low:6.32

Shares:4.05M

Float Shares:3.56M

Volume Ratio:1.54

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.27

EPS(LYR):45.37

ROE:--

ROA:-22.50%

PB:-1.04

PE(LYR):0.17

Loading ...

Overview Company News Filings

Oppenheimer Keeps Their Buy Rating on Kyntra Bio (KYNB)

Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)

Kyntra Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Kyntra Bio Posts Investor Presentation Highlighting FG-3246/fg-3180 Phase 2 Program in Prostate Cancer

Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate

Benzinga Earnings

Kyntra Bio Q2 FY26 Returns to Profit at $12 Million; Revenue Turns to $(1.5) Million

Kyntra Bio Inc Q2 Net Income from Cont Ops USD 11.974 Million

Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview

Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview

Kyntra Bio Schedules Second-Quarter 2026 Results Conference Call

Kyntra Bio Inc : Oppenheimer Initiates Coverage with Outperform Rating; Target Price $35

THOMSON REUTERS

Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting

BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes

Kyntra Bio to present additional MATTERHORN trial data at EHA

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients With Anemia Due to Lower-Risk Myelodysplastic Syndromes

THOMSON REUTERS

Kyntra Bio - Roxadustat Shows No New Safety Signals in Lr-Mds Patients

THOMSON REUTERS

Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS

Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca

MT Newswires Live

Kyntra Bio Initiated at Buy by Rodman & Renshaw

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/KYNB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.74,"timestamp":1787580202276,"preClose":7.52,"halted":0,"volume":3387,"delay":0,"changeRate":0.029255319148936258,"floatShares":3561200,"shares":4045445,"eps":45.266125,"marketStatus":"Trading","change":0.22,"latestTime":"08-24 10:04:28 EDT","open":7.67,"high":7.74,"low":7.67,"amount":26050.118109000003,"amplitude":0.009309,"askPrice":7.7,"askSize":300,"bidPrice":7.67,"bidSize":102,"shortable":3,"etf":0,"ttmEps":45.266125,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":7.52,"preHourTrading":{"tag":"盘前","latestPrice":7.69,"preClose":7.52,"latestTime":"08:42 EDT","volume":10,"amount":76.9,"timestamp":1787575320174,"change":0.17,"changeRate":0.022606,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.52,"preClose":7.52,"latestTime":"19:30 EDT","volume":60,"amount":458.4146,"timestamp":1787355005170,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.543417},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3561200,"roa":"-22.50%","roe":"--","lyrEps":45.371456,"volumeRatio":1.543417,"shares":4045445,"dividePrice":0,"high":7.74,"amplitude":0.009309,"preClose":7.52,"low":7.67,"week52Low":6.32,"pbRate":"-1.04","psRate":"6.78","week52High":12.6,"institutionHeld":0,"latestPrice":7.74,"committee":-0.492537,"eps":45.266125,"divideRate":0,"volume":3387,"delay":0,"ttmEps":45.266125,"open":7.67,"prevYearClose":8.78,"prevWeekClose":7.52,"prevMonthClose":6.73,"prevQuarterClose":7.55,"fiveDayClose":6.81,"twentyDayClose":7.05,"sixtyDayClose":7.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"KYNB","fiscalQuarterEnding":"2026/06","expectedEps":-3.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-4.68},{"market":"US","date":"2026-05-11","symbol":"KYNB","fiscalQuarterEnding":"2026/03","expectedEps":-3.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-3.74},{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-08-21","current":0.166129,"percent":0.487013,"low":0.128311,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"high":0.188779,"avg":0.161409,"sd":0.014739,"marketCap":29639587},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248},{"date":"2026-04-02","current":0.156621,"twenty":0.135327,"median":0.1489,"eighty":0.163094,"marketCap":28732471},{"date":"2026-04-10","current":0.158607,"twenty":0.13649,"median":0.150021,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-17","current":0.158607,"twenty":0.137128,"median":0.152651,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-24","current":0.154658,"twenty":0.137616,"median":0.154087,"eighty":0.16165,"marketCap":28372304},{"date":"2026-05-01","current":0.160371,"twenty":0.138929,"median":0.154658,"eighty":0.161209,"marketCap":29420432},{"date":"2026-05-08","current":0.156671,"twenty":0.140092,"median":0.155492,"eighty":0.161033,"marketCap":28741595},{"date":"2026-05-15","current":0.173439,"twenty":0.140542,"median":0.155518,"eighty":0.16165,"marketCap":28377265},{"date":"2026-05-22","current":0.171707,"twenty":0.141779,"median":0.155761,"eighty":0.163953,"marketCap":28093897},{"date":"2026-05-29","current":0.173687,"twenty":0.143209,"median":0.156128,"eighty":0.168258,"marketCap":28417746},{"date":"2026-06-05","current":0.168491,"twenty":0.144709,"median":0.156621,"eighty":0.168887,"marketCap":27567642},{"date":"2026-06-12","current":0.167254,"twenty":0.145601,"median":0.156867,"eighty":0.168639,"marketCap":27365237},{"date":"2026-06-18","current":0.170965,"twenty":0.145982,"median":0.157197,"eighty":0.169431,"marketCap":27972453},{"date":"2026-06-26","current":0.171707,"twenty":0.14617,"median":0.158138,"eighty":0.170144,"marketCap":28093897},{"date":"2026-07-02","current":0.1868,"twenty":0.14632,"median":0.158607,"eighty":0.170718,"marketCap":30563245},{"date":"2026-07-10","current":0.181109,"twenty":0.146883,"median":0.158743,"eighty":0.171457,"marketCap":29632179},{"date":"2026-07-17","current":0.182841,"twenty":0.14707,"median":0.160014,"eighty":0.171955,"marketCap":29915547},{"date":"2026-07-24","current":0.174924,"twenty":0.147445,"median":0.160711,"eighty":0.173192,"marketCap":28620151},{"date":"2026-07-31","current":0.167996,"twenty":0.147746,"median":0.161253,"eighty":0.173241,"marketCap":27486680},{"date":"2026-08-07","current":0.172709,"twenty":0.148684,"median":0.162522,"eighty":0.173005,"marketCap":28257845},{"date":"2026-08-14","current":0.174182,"twenty":0.14943,"median":0.163953,"eighty":0.173489,"marketCap":28498708},{"date":"2026-08-21","current":0.161795,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"marketCap":29639587}],"updateTime":1787576605570},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659014431","title":"Oppenheimer Keeps Their Buy Rating on Kyntra Bio (KYNB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659014431","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659014431?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:56","pubTimestamp":1786712193,"startTime":"0","endTime":"0","summary":"In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Kyntra Bio, with a price target of $35.00. According to TipRanks,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-kyntra-bio-kynb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-kyntra-bio-kynb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186112","title":"Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186112?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:00","pubTimestamp":1786698042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kyntra Bio (KYNB) and Minerva Neurosciences (NERV). Kyntra Bio (K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kyntra-bio-kynb-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kyntra-bio-kynb-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","LU0029874061.USD","NERV","KYNB","HCSG","BK4137","XLV","LU0128526141.USD","BK4585","LABU","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659602921","title":"Kyntra Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659602921","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659602921?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654941,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings SummaryKyntra Bio, Inc.KYNB.OQreported a quarterly adjusted loss of $4.69 per share for the quarter ended June 30, lower than ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A28Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659916760","title":"Kyntra Bio Posts Investor Presentation Highlighting FG-3246/fg-3180 Phase 2 Program in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659916760?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:23","pubTimestamp":1786652638,"startTime":"0","endTime":"0","summary":"Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancerKyntra Bio highlighted Phase 2 enrollment for FG-3246 monotherapy in metastatic castration-resista","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6YM2jf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162600","title":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162600","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162600?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651605,"startTime":"0","endTime":"0","summary":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/KYNB","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659898162","title":"Kyntra Bio Q2 FY26 Returns to Profit at $12 Million; Revenue Turns to $(1.5) Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659898162","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659898162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651478,"startTime":"0","endTime":"0","summary":"Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) millionKyntra Bio posted Q2 revenue of $(1.47) million, swinging from $1.35 million a year earlier.Net income from continui","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL5d1hfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","BCDF","NDAQ","KYNB","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416400","title":"Kyntra Bio Inc Q2 Net Income from Cont Ops USD 11.974 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416400","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416400?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:03","pubTimestamp":1786651380,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Inc Q2 Net Income From Cont Ops USD 11.974 MillionAug 13 (Reuters) - Kyntra Bio Inc Q2 net income USD 11.974 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX8QJ8PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659683162","title":"Press Release: Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659683162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659683162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer , continues enrolling with interim analysis on. -- Phase 3 protocol of roxadustat for the treatment of anemia in patients. burden  has been finalized with the goal to initiate the. -- Additional data from the Phase 3 MATTERHORN study were presented at the. improvements in transfusion independence in patients with HTB and. -- Cash, cash equivalents, investments, and accounts receivable of $95.7. -- Kyntra Bio to host conference call and webcast presentation today at 5:00. first-in-class ADC targeting CD46 in mCRPC continues; interim analysis is. on track for the fourth quarter of 2026.Roxadustat-- Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia. in patients with LR-MDS and high transfusion burden  has been. -- In a post hoc analysis of the Phase 3 MATTERHORN study, patients. treated with roxadustat showed a clinically meaningful improvement. in transfusion independence ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HTB","BK4022","LU2236285917.USD","TM","BK4211","BK4099","BK4080","BK4231","03160","BK4206","BK4588","NETL","LU0052756011.USD","KYNB","LU0128525689.USD","LU0211328371.USD","LU0310799852.SGD","DD","ADC","BK4232","BK4604","LU1267930227.SGD","BK4139","LU0211327993.USD","R","BK4555","BK4109","LU0310800965.SGD","LU1267930490.SGD","BK4585","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945542","title":"Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945542","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945542?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:43","pubTimestamp":1786480986,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. <KYNB.OQ> expected to post a loss of $3.18 a share - Earnings PreviewKyntra Bio, Inc.KYNB.OQKYNB.Ois expected to  show a rise in quarterly revenue when it reports  results on August 1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448247:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644259","title":"Kyntra Bio, Inc. Expected to Post a Loss of $3.18 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644259","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644259?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:39","pubTimestamp":1786113576,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. <KYNB.OQ> expected to post a loss of $3.18 a share - Earnings PreviewKyntra Bio, Inc.KYNB.OQKYNB.Ois expected to  show a rise in quarterly revenue when it reports  results on August 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657130634","title":"Kyntra Bio Schedules Second-Quarter 2026 Results Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2657130634","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657130634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:01","pubTimestamp":1786021280,"startTime":"0","endTime":"0","summary":"Kyntra Bio schedules second-quarter 2026 results conference callKyntra Bio will release second-quarter 2026 financial results on Aug. 13.A conference call starts Aug. 13 at 5:00 p.m. ET, with a webcas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2sZgrR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","SG9999014021.USD","BK4139","BCDF","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649198791","title":"Kyntra Bio Inc : Oppenheimer Initiates Coverage with Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2649198791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649198791?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:18","pubTimestamp":1783426716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643755873","title":"Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643755873","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643755873?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:02","pubTimestamp":1781604143,"startTime":"0","endTime":"0","summary":"Kyntra Bio held its annual shareholder meeting on June 12, 2026.Shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2vhk07:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346662","title":"BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642346662?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:35","pubTimestamp":1781210145,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic SyndromesJune 11 (Reuters) - Kyntra Bio Inc KYNB.O:KYNTRA BIO PRESENTS NEW ROXAD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642159234","title":"Kyntra Bio to present additional MATTERHORN trial data at EHA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642159234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642159234?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:20","pubTimestamp":1781209200,"startTime":"0","endTime":"0","summary":"Kyntra Bio (KYNB) announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with ane...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-to-present-additional-matterhorn-trial-data-at-eha-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-to-present-additional-matterhorn-trial-data-at-eha-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642319002","title":"Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients With Anemia Due to Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642319002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642319002?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231137","title":"Kyntra Bio - Roxadustat Shows No New Safety Signals in Lr-Mds Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231137?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208349,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0YU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642151231","title":"Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2642151231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642151231?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208347,"startTime":"0","endTime":"0","summary":"Kyntra Bio flagged new post hoc Phase 3 MATTERHORN data on roxadustat in lower-risk MDS anemia, set for presentation at EHA 2026.The analysis showed higher transfusion independence with roxadustat versus placebo, supporting a potential differentiated option in a hard-to-treat setting.Benefits appeared consistent across ring sideroblast-positive and ring sideroblast-negative disease, widening the potential addressable patient pool.A pivotal Phase 3 trial in high transfusion burden patients is being finalized with FDA input, with initiation targeted for 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLtvM8m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","KYNB","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286344","title":"Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286344?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:00","pubTimestamp":1781089211,"startTime":"0","endTime":"0","summary":"Kyntra Bio  has received $4 million from AstraZeneca Treasury , completing the payments for their 2025 share purchase agreement, Kyntra Bio said in a Tuesday filing.In 2025, Kyntra Bio sold its Chinese operations to AstraZeneca for about approximately $220 million and the $4 million payment is second and final holdback under the deal, according to the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","LU2237443895.HKD","LU0320765992.SGD","LU2236285917.USD","BK4007","AZNH","LU1829250122.USD","LU2456880835.USD","KYNB","LU0289739699.SGD","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","BK4585","LU2462157665.USD","BK4139","LU2237443465.HKD","LU2237443622.USD","IE00B3T34201.USD","LU2237443382.USD","AZN","BK4588","LU0058720904.USD","BK4568","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642584467","title":"Kyntra Bio Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2642584467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642584467?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:01","pubTimestamp":1781006460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYNB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 08:01 ET (12:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}